For the first time, a drug candidate created entirely by artificial intelligence has reached human testing. The compound, a flu vaccine booster developed by an AI system called SAM (Smart Algorithms for Medical Discovery), is now undergoing clinical trials at multiple sites across the United States.
The breakthrough comes from researchers at Flinders University in Australia, who designed SAM to accelerate drug discovery—a process that traditionally costs billions of dollars and often ends in failure before human trials even begin.
Nikolai Petrovsky, a researcher involved in the project, explained that the team fed SAM data on chemical compounds that either activate or have no effect on the human immune system. Using that information, the AI generated trillions of potential chemical structures and ranked them for likely effectiveness.
From Algorithm to Lab Bench
After SAM identified its top candidates, the researchers synthesized a selection and tested them on human blood cells in the lab. One candidate stood out: a molecule that acts as a "turbocharger" for flu vaccines, significantly boosting immune response. In animal studies, the compound proved highly effective.
Now, with clinical trials underway in the US, the question is whether the AI-designed vaccine will perform as well in humans. If successful, it could pave the way for a new era where artificial intelligence plays a central role in developing treatments for a range of diseases.
The development is part of a broader trend in the pharmaceutical industry, where companies are increasingly turning to machine learning to cut costs and speed up the discovery pipeline. However, SAM's achievement stands out because the AI was responsible for the entire design process, not just a single step.
While the outcome of the trials remains uncertain, the fact that an AI-generated drug has reached human testing is a significant milestone. It suggests that algorithms can handle the complexity of drug design, potentially leading to faster responses to emerging health threats.
For now, the flu vaccine candidate is being evaluated for safety and efficacy in humans. If all goes well, it could eventually contribute to reducing the burden of seasonal influenza, which causes millions of illnesses and hundreds of thousands of deaths worldwide each year.
The research team at Flinders University is not resting on its laurels. They see SAM as a platform that could be adapted to develop vaccines and treatments for other infectious diseases, though any such applications would require their own rigorous testing and regulatory approval.
As the trials progress, the scientific community will be watching closely. The success or failure of this AI-designed vaccine will likely influence how quickly the pharmaceutical industry embraces artificial intelligence in the years to come.